

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 December 2008 (31.12.2008)

PCT

(10) International Publication Number
WO 2009/000412 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) *C07D 487/04* (2006.01)
C07D 471/14 (2006.01) *C07D 491/14* (2006.01)

Deutschland GmbH, 65926 Frankfurt am Main (DE).
HALLAND, Nis [DK/DE]; Sanofi-Aventis Deutschland
GmbH, 65926 Frankfurt am Main (DE).

(21) International Application Number:

PCT/EP2008/004638

(74) **Agent: THEN, Johann**; Sanofi-Aventis Deutschland
GmbH, Patents Germany, Industriepark Höchst, Gebäude
K 801, 65926 Frankfurt am Main (DE).

(22) International Filing Date: 11 June 2008 (11.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

07290801.5 26 June 2007 (26.06.2007) EP

(71) **Applicant** (for all designated States except US): **SANOFI
AVENTIS** [FR/FR]; 174 Avenue De France, F-75013 Paris
(FR).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **ALONSO, Jorge**
[ES/DE]; Sanofi-Aventis Deutschland GmbH, 65926
Frankfurt am Main (DE). **LINDENSCHMIDT, Andreas**
[DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926
Frankfurt am Main (DE). **NAZARE, Marc** [DE/DE]; c/o
Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am
Main (DE). **R'KYEN, Omar** [MA/DE]; Sanofi-Aventis
Deutschland GmbH, 65926 Frankfurt am Main (DE).
URMANN, Mathias [DE/DE]; c/o Sanofi-Aventis


(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC,
LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) **Title:** A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES



(I)

(57) **Abstract:** A regioselective metal catalyzed synthesis of benzimidazoles and azabenzimidazoles. The present invention relates to a process for the regioselective synthesis of compounds of the formula (I), wherein R¹; R²; R³; R⁴; J¹; J²; J³; J⁴ and G have the meanings indicated in the claims. The present invention provides a direct metal, e.g. palladium or copper, catalyzed, regioselective process to a wide variety of unsymmetrical, multifunctional N-substituted benzimidazoles or azabenzimidazoles of formula (I) starting from 2-halo- nitroarenes and N-substituted amides useful for the production of pharmaceuticals, diagnostic agents, liquid crystals, polymers, herbicides, fungicides, nematocides, parasiticides,


insecticides, acaricides and arthropodocides.

A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles

Field of the Invention

5

The present invention relates to a process for the regioselective synthesis of compounds of the formula (I),



wherein R1; R2; R3; R4; J1; J2; J3; J4 and G have the meanings indicated below and which are useful as intermediates for the preparation of valuable pharmaceutically active ingredients.

Background of the Invention

The present invention relates to a direct metal catalyzed, regioselective process for the preparation of a wide variety of unsymmetrical, multifunctional annelated benzimidazoles or azabenzimidazoles of the formula (I) starting from 2-halo-nitroarenes and lactames. Preferred metals are palladium and copper.

Annelated benzimidazoles play an important role in drug discovery and can certainly be regarded as privileged structures in pharmaceutical research. Several benzimidazole derivatives containing fused ring structures have anti-inflammatory, analgesic, antiarthritic, antitumor activity, or a combination of this activities (A. J. Charlson, J. S. Harrington, *Carbohydrate Research* **1975**, *43*, 383-387; P. Bender U.S. Patent 4186205, 1980; *Chem. Abstr.* **1980**, *92*, 181195; H. G. Alpermann *Arzneim.-Forsch.* **1966**, *16*, 1641; R. Zhou, E. B. Skibo *J. Med. Chem.* **1996**, *39*, 4321-4331).

25

In contrast to the great importance of this scaffold no general regioselective route to annelated benzimidazoles und annelated benzimidazoles has been described yet. The few methods available so far are multi-step processes often requiring harsh reaction

conditions and are restricted in the substrate range, have poor cost-effectiveness and are thus of limited use (J. R. McLure, J. H. Custer, H. D. Schwarz, D. A. Lill, *Synlett*, 710-712; E. B. Skibo, I. Islam, W. G. Schulz, R. Zhou, L. Bess, R. Boruah *Synlett*, **1996**, 297-309; F. Aldabbagh, W. R. Bowman *Tetrahedron* **1999**, 55, 4109-4122).

5

Although palladium-catalyzed protocols for the cross-coupling between aryl halides and lactams have been reported (J. Yin, S. L. Buchwald *Org. Lett.* **2000**, 2, 1101-1104; D. J. Madar, H. Kopecka, D. Pireh, J. Pease, M. Pliushchev, R. J. Sciotti, P. E. Wiedeman, S. W. Djuric *Tetrahedron Lett.* **2001**, 42, 3681-3684), only one example
10 employing a 2-halo-nitroarene derivative has been reported. R. G. Browning, V. Badarinarayana, H. Mahmud, C. J. Lovely, describe in this example the coupling of 1-bromo-2-nitro-benzene and a pyrrolidin-2-one derivative in moderate yield (*Tetrahedron* **2004**, 60, 359-365).

Although copper-catalyzed protocols for the cross-coupling between aryl halides and
15 lactams have been reported, very few examples employing 2-halo-nitroarenes exist. Wei Deng, Ye-Feng Wang, Yan Zou, Lei Liu, Qing-Xiang Guo describe the coupling of 1-iodo-2-nitrobenzene with pyrrolidine-2-one (*Tetrahedron Lett.* **2004**, 45, 2311-2315).

However, no general applicability for the palladium-catalyzed cross-coupling of 2-halo-
20 nitroarenes, in particular 2-chloro-nitroarenes, and lactams was shown, and in addition no use was made to for the regioselective synthesis of annelated benzimidazoles or azabenzimidazoles.


The limited regioselective access annelated benzimidazoles or azabenzimidazoles often prevents the optimization of a potential drug substance or substance with for
25 example agricultural application and is accompanied by poor cost-effectiveness. Thus the present invention is useful in preparing intermediates or end products of biological active compounds in pharmaceutical and agricultural applications.

Summary of the invention

30 The present invention provides a direct metal catalyzed, regioselective synthetic route to a wide variety of unsymmetrical, multifunctional annelated benzimidazoles or azabenzimidazoles of formula I starting from 2-halo-nitroarenes of formula II and


lactames of formula III. Preferred metals are palladium and copper. Thus one aspect of the invention is an efficient and general palladium catalyzed coupling method for substituted 2-halo-nitroarenes (step 1) to intermediates of formula IV. In another aspect of the invention, an efficient process is provided for the subsequent reductive aminocyclisation (step 2) of intermediates of formula IV, which can be either performed with the crude reaction mixture of step 1 or optionally after simple filtration through a pad of celite by using a reducing reagent.

The advantages of the provided process are that it comprises a novel, direct regioselective catalytic, mild and general method for the synthesis of annelated benzimidazoles or azabenzimidazoles, which also can be performed as a one-pot procedure. Thus, the process is very time- and cost-effective. Moreover, are the reaction conditions compatible with a broad range of functional groups and a large variety of starting materials, which are easily accessible or even commercially available.



Detailed description of the invention

A process for preparing a compound of formula I



and/or all stereoisomeric forms of the compound of formula I, and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of formula I, wherein

- 5 J1, J2, J3 and J4 are independently from each other selected from carbon or nitrogen atoms and form together with the carbon atoms they are attached to a stable aromatic or heteroaromatic ring,

- G is monocyclic, bicyclic or tricyclic 4- to 15-membered saturated, or partially unsaturated heterocyclic ring containing in addition to the nitrogen atom of the lactam moiety 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclic ring is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by oxo or by R5,
- 10

R1, R2, R3, R4 and R5 are independent of one another identical or different and are

- a) hydrogen atom,
- 15 b) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- c) halogen,
- d) phenyloxy-, wherein phenyloxy is unsubstituted or substituted one to three times by R13,
- 20 e) $-(C_1-C_3)$ -fluoroalkyl,
- f) $-N(R_{10})-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- g) $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- 25 h) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,

- i) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- j) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- k) $-O-CF_3$,
- l) $-O-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- m) $-NO_2$,
- n) $-CN$,
- o) $-OH$,
- p) $-C(O)-R_{10}$,
- q) $-C(O)-O-R_{11}$,
- r) $-C(O)-N(R_{11})-R_{12}$,
- s) $-N(R_{11})-R_{12}$,
- t) $-N(R_{10})-SO_2-R_{10}$,
- v) $-S-R_{10}$,
- w) $-SO_n-R_{10}$, wherein n is 1 or 2,
- x) $-SO_2-N(R_{11})-R_{12}$ or
- y) at least one of R1, R2, R3 or R4 are absent in case one or more of J1, J2, J3 or J4 are nitrogen atom, or

R1 and R2, R2 and R3 or R3 and R4 form together with the atoms which they are attached to a 5- or 8- membered ring, containing up to 0, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said ring is unsubstituted or substituted one, two, three or four times by R14,

R10 is hydrogen atom, $-(C_1-C_3)$ -fluoroalkyl or $-(C_1-C_6)$ -alkyl,

R11 and R12 are independently of one another identical or different and are

- a) hydrogen atom,
- b) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

- c) $-(C_6-C_{14})$ -aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 d) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13 or


5 R13 is halogen, $-NO_2$, $-CN$, $=O$, $-OH$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkoxy, $-CF_3$, phenyloxy-, $-C(O)-R_{10}$, $-C(O)-O-R_{17}$, $-C(O)-N(R_{17})-R_{18}$, $-N(R_{17})-R_{18}$, $-N(R_{10})-SO_2-R_{10}$, $-S-R_{10}$, $-SO_n-R_{10}$, wherein n is 1 or 2, $-SO_2-N(R_{17})-R_{18}$, $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl
 10 is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or
 15 trisubstituted independently of one another by R14,

R14 is halogen, $-OH$, $=O$, $-CN$, $-CF_3$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_4)$ -alkoxy, $-NO_2$, $-C(O)-OH$, $-NH_2$, $-C(O)-O-(C_1-C_4)$ -alkyl, $-(C_1-C_8)$ -alkylsulfonyl, $-C(O)-NH-(C_1-C_8)$ -alkyl, $-C(O)-N-[(C_1-C_8)\text{-alkyl}]_2$, $-C(O)-NH_2$, $-S-R_{10}$, $-N(R_{10})-C(O)-NH-(C_1-C_8)$ -alkyl, or $-N(R_{10})-C(O)-N-[(C_1-C_8)\text{-alkyl}]_2$,

20 R17 and R18 are independently of one another identical or different and are


- a) hydrogen atom,
 b) $-(C_1-C_6)$ -alkyl,
 c) $-(C_6-C_{14})$ -aryl- or
 d) $-(C_4-C_{14})$ -heteroaryl,

25 said process comprises a reaction of a compound of formula II




wherein R1, R2, R3, R4, J1, J2, J3 and J4 are as defined in formula I and

X is Cl, Br, I, triflate or nonaflate, with a compound of formula III



wherein ring G are as defined in formula I,

in the presence of a metal catalyst, a base, a ligand and an aprotic solvent to give a
5 compound of formula IV



and converting the compound of formula IV into a compound of formula I in the
presence of a reducing reagent and a second solvent and
optionally the compound of formula I is converted to its physiologically tolerated salt.

10

The present invention also relates to a process for the preparation of a compound of
formula I, wherein palladium or copper are used as a metal catalyst.

15

The present invention also relates to a process for the preparation of a compound of
formula I, wherein

J1, J2, J3 and J4 form together with the carbon atoms they are attached to a ring
selected from benzene, pyrazine, pyridazine, pyridine, pyrimidine, triazine or
tetrazine,

20

G is selected from azetidine, azepane, azocane, aza-bicyclo[2.2.1]heptane, aza-
bicyclo[2.2.2]octane, azacyclooctanone, azacyclononanone, aza-tricyclo
[4.3.1.1*3,8*]undecane, 4,4-dimethyl-3,5-dioxa-azatricyclo[5.2.1.0*2,6*]-decane,
3,5-dioxa-azatricyclo-[5.2.1.0*2,6*]decane, 4,4-dimethyl-3,5-dioxa-azatricyclo
[5.2.1.0*2,6*]decan-9-one, azocane-2-one, azonane, 1,4-diazepane,
[1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, imidazoline,
imidazolidine, isothiazolidine, isoxazolidine, ketopiperazine, morpholine,
25 [1,4]oxazocane, [1,3]oxazocan-2-one, piperazine, piperidine, pyrazoline,

pyrazolidine, 1,2-dihydro-pyridine, pyrrolidine, pyrrolidinone, 2,3-dihydro-1H-pyrrole, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydropyridine, thiadiazine, thiazolidine, thiazoline, thiomorpholine,
wherein G is unsubstituted or mono-, di-, tri- or four times substituted

5 independently of one another by oxo or by R5,

R1, R2, R3, R4 and R5 are independent of one another identical or different and are

a) hydrogen atom,

b) F,

c) Cl,

10 d) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,

e) $-(C_1-C_3)$ -fluoroalkyl,

f) phenyl, wherein phenyl is unsubstituted or substituted one to three times by R13,

15 g) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is selected from acridinyl, azaindole (1H-pyrrolopyridinyl), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl,
20 cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazoliny, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 3,3-dioxo[1,3,4]oxathiazinyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, indanyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl,
25 oxazolidinyl, oxazolinyl, oxazolyl, oxetanyl, oxocanyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl,

30

pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, and is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,

h) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di-

, tri- or four times substituted independently of one another by R13, or

i) a 3- to 7-membered cyclic residue selected from azepine, azetidine, aziridine, azirine, 1,4 diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxetan, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, and is unsubstituted or mono-, di-, tri- or four times substituted

independently of one another by R13,

j) $-O-CF_3$,

- k) -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- l) -N(R10)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- 5 m) -CN,
- n) -OH,
- o) phenyloxy-, wherein phenyloxy is unsubstituted or substituted one to three times by R13,
- p) -C(O)-O-R11,
- 10 q) -C(O)-N(R11)-R12,
- r) -N(R11)-R12,
- s) -N(R10)-SO₂-R10,
- t) -S-R10,
- v) -SO_n-R10, wherein n is 1 or 2,
- 15 w) -SO₂-N(R11)-R12,
- x) -C(O)-R10 or
- y) at least one of R1, R2, R3 or R4 are absent in case one or more of J1, J2, J3 or J4 are nitrogen atom,
- R10 is hydrogen atom, -(C₁-C₃)-fluoroalkyl or -(C₁-C₆)-alkyl,
- 20 R11 and R12 are independently of one another identical or different and are
- a) hydrogen atom,
- b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25 d) -(C₄-C₁₄)-heteroaryl, wherein heteroaryl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13 or
- R13 is F, Cl, -CN, =O, -OH, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, -CF₃, phenyloxy-,
- 30 -C(O)-R10, -C(O)-O-R17, -C(O)-N(R17)-R18, -N(R17)-R18, -N(R10)-SO₂-R10, -S-R10, -SO_n-R10, wherein n is 1 or 2, -SO₂-N(R17)-R18, phenyl, wherein

phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C₄-C₁₄)-heteroaryl, wherein heteroaryl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C₃-C₆)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or a 3- to 7-membered cyclic residue, which is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is F, Cl, -OH, =O, -CN, -CF₃, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -C(O)-OH, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -S-R10, -N(R10)-C(O)-NH-(C₁-C₈)-alkyl or -N(R10)-C(O)-N-[(C₁-C₈)-alkyl]₂,

R17 and R18 are independently of one another identical or different and are

- a) hydrogen atom,
- b) -(C₁-C₄)-alkyl,
- c) phenyl or
- d) -(C₄-C₁₄)-heteroaryl, wherein heteroaryl is as defined above and

X is Cl, Br or I.

The invention also relates to a process for the preparation of a compound of formula I, which are

2,3-Dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;

7-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;

6-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;

7-Methoxy-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;

5-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole-6-carboxylic acid methyl ester;

2-Methoxy-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine;

2,6-Dimethyl-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine;

1,2,3,4-Tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine;

3,9-Dimethyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*;3',2'-*d*]imidazole;

7-Chloro-4,4-diphenyl-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine;

Dimethyl-(S)-7,8,9,10-tetrahydro-6*H*-benzo[4,5]imidazo[1,2-*a*]azepin-6-yl-amine;
3-Methyl-5,6,7,8,9,10-hexahydro-4,4b,11-triaza-cycloocta[*a*]indene;
2-Methyl-6,7,8,9,10,11-hexahydro-5*H*-4,4b,12-triaza-cyclonona[*a*]indene,
3-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*;3',2'-*d*]imidazole,
5 2-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*:3',2'-*d*]imidazole,
5,6,7,8,9,10-Hexahydro-1,4b,11-triaza-cyclooct[*a*]indene, or
3-Methoxy-6,7,8,9,10,11-hexahydro-5*H*-4b,12-diaza-cyclonon[*a*]indene.

The aprotic solvent useful for step 1 in the process of the present invention must be
10 solvent, wherein the compounds of formulae II, III and IV, metal catalyst, base and
ligand are soluble or at least partially soluble and compatible and is chemically inert
under the reaction conditions and does not contain water or oxygen as impurities.
Examples of said aprotic solvents are: benzene, toluene, xylene, mesitylene,
acetonitrile, tetrahydrofuran, dimethylformamide, *n*-methylpyrrolidinone,
15 dimethylacetamide, dimethylsulfoxide, diglyme ((2-methoxyethyl)ether) or pyridine.
Preferred is benzene, mesitylene or toluene. Most preferred is toluene.

The base useful in this process of the present invention is a basic organic or inorganic
compound and acts as proton acceptor without inhibiting the catalytic activity of the
20 employed metal catalyst e.g. palladium or copper species or preventing the coupled
intermediate species of the compound of formula IV to undergo the reductive
aminocyclisation. Suitable classes of such bases are for example carbonates,
phosphates, fluorides, alkoxides and hydroxides with a suitable metal as counter ion.
Carbonates and phosphates are the preferred bases in the process of the present
25 invention. Potassium carbonate or potassium phosphate and in particular caesium
carbonate are the preferred bases.

The bases are generally employed in moderate excess based on the 2-halo-nitroarene
of the compound of formula II. A useful range is a 1.1 to 2 fold excess based on the 2-
30 halo-nitroarene of the compound of formula II. The base may be favourably employed
in a 1.4 fold excess based on the 2-halo-nitroarene of the compound of formula I.

The palladium catalyst useful in this process can be selected from the following classes: Pd-alkanoates, Pd-alkanoate complexes, Pd-acetonates, Pd-halides, Pd-halide complexes, Pd-phosphine complexes. Representative examples include, but are not limited to: palladium (II) acetate, palladium (II) trifluoroacetate,

5 tris(dibenzylideneacetone)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0) chloroform adduct, palladium (II) chloride, 2,2'-bis(diphenylphosphino)-1,1'-binaphthylpalladium(II) chloride, acetato(2'-di-tert-butylphosphino-1,1'-biphenyl-2-yl)palladium(II), (1,2-Bis(diphenylphosphino)ethane)dichloropalladium(II), Bis[1,2-bis(diphenylphosphino)ethane]palladium (0), [(2S,3S)-Bis(diphenylphosphino)butane]

10 [eta3-allyl]palladium(II) perchlorate, 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer. The preferred catalysts are palladium (II) acetate, 2,2'-bis(diphenylphosphino)-1,1'-binaphthylpalladium(II) and in particular palladium (II) trifluoroacetate.

15 The palladium catalyst is generally employed in an amount in the range of 1 to 10 mole percent based on the 2-halo-nitroarene of the compound of formula II. A useful range is 1 to 9 mole percent of palladium catalyst based on the 2-halo-nitroarene of the compound of formula I.

20 The ligand useful in this process with palladium catalyst is a mono- or bidentate phosphine ligand and can be selected from the following compounds, but are not limited to: (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene, (9,9-dimethyl-9h-xanthene-4,5-diyl)bis[diphenyl phosphine], (R)-(-)-1-[(S)-2-(diphenylphosphino)ferrocenyl] ethyldicyclohexylphosphine, 1,2-Bis(diphenylphosphino)ethane, 1,3-

25 Bis(diphenylphosphino)propane, (R)-(-)-1-[(S)-2-(Dicyclohexylphosphino)ferrocenyl]-ethyldi-tert-butylphosphine, (R)-(+)-1,1'-Bis(diphenylphosphino)-2,2'-bis(*N,N*-diisopropylamido)ferrocene, (S,S)-1-[1-(Di-*tert*-butylphosphino)ethyl]-2-(diphenylphosphino)ferrocene, (1*R*,2*R*)-(+)-1,2-Diaminocyclohexane-*N,N'*-bis(2-diphenylphosphino-1-naphthyl), (-)-1,2-Bis((2*S*,5*S*)-2,5-diiso-propylphospholano)-

30 benzene, Bis[(2-diphenylphosphino)phenyl]ether, (S)-(-)-2,2'-Bis(di-para-tolylphosphino)-1,1'-binaphthyl, 4,5-Bis(bis(3,5-bis(trifluoromethyl)phenyl)-phosphino)-

9,9-dimethylxanthen, 2,2'-bis[(2',4',6'-triisopropyl)dicyclohexylphosphino]-biphenyl, 2,2'-bis(di-*tert*-butylphosphino)biphenyl, tri-*tert*-butylphosphine.

Most favourably (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene or (9,9-dimethyl-9h-xanthene-4,5-diyl)bis[diphenyl phosphine] are employed in particular in combination
 5 with a palladium source bearing no phosphine itself, like e.g. palladium (II) acetate, palladium (II) trifluoroacetate, tris(dibenzylideneacetone)dipalladium(0), palladium (II) chloride. The most preferred ligand is (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene.

10 The phosphine ligand is generally employed in an amount in the range of 1 to 10 mole percent based on the 2-halo-nitroarene of the compound of the compound of formula II. A useful range is 1 to 9 mole percent of phosphine ligand based on the 2-halo-nitroarene of the compound of formula II. Most favourably the phosphine ligand is employed in an equimolar ratio with respect to the palladium source.

15

The copper catalyst useful in this process can be selected from the following classes: copper (I) halogen salts and copper oxides. Representative examples include, but are not limited to: copper (I) chloride, copper (I) bromide, copper (I) iodide and copper (I) oxide. The preferred catalyst is copper (I) iodide.

20 The copper catalyst is generally employed in an amount in the range of 0.1 to 30 mole percent based on the 2-halo-nitroarene of the compound of formula II. A useful range is 1 to 9 mole percent of copper catalyst based on the 2-halo-nitroarene of the compound of formula I.

25 The ligands useful in this process with copper catalyst are a mono- or bidentate amine ligand and can be selected from the following compounds, but are not limited to: ethylenediamine, *N*-methylethylenediamine, *N,N'*-dimethyl-ethane-1,2-diamine, *N,N*-dimethyl-ethane-1,2-diamine *N*-buthylethylenediamine, *N,N*-dimethylethylenediamine, *N,N,N'*-trimethylthylenediamine, *N,N,N,N'*-tetramethylthylenediamine, *trans*-1,2-cyclohexanodiamine, *cis*-1,2-cyclohexanodiamine, *cis/trans*-1,2-cyclohexanodiamine,
 30 *N,N'*-dimethyl-1,2-cyclohexanodiamine, *N,N'*-diethyl-1,2-cyclohexanodiamine, *N,N'*-dipropyl-1,2-cyclohexanodiamine, 1,3-propylenediamine, 1,2-benzenediamine,

- phenanthridine, acridine, acridine orange, 9-aminoacridine, 9-hydroxy-4-methoxyacridine, proflavine, 4-(2-pyriylazo) resorcinol, 1,2-dihydro-1-(2-(2-pyridyl)-ethyl)-3,6-pyridazinedione, [1,10]phenanthroline, 5-nitro-[1,10]phenanthroline, bathophenanthroline, spiramycin, bichinchonic acid sodium salt (bca), 1-(4-pyridyl)
- 5 pyridinium chloride, 2-pyridylacetic acid hydrochloride, 8-mercaptoquinoline hydrochloride, dimethylamino acetic acid, picolinic acid, 3-hydroxypicolinic acid, 3-hydroxy picolinamide, glycol, pyridine, 2-aminopyridine, 2-hydroxypyridine, 3-cyanopyridine, 4-cyanopyridine, 2-ethylpyridine, 2-amino-6-methylpyridine, 2-(aminomethylpyridine), 2-(hydroxymethylpyridine), 2-hydroxi-6-methylpyridine, 2-
- 10 dimethylaminopyridine, 4-dimethylaminopyridine, 2-(2-hydroxyethyl)pyridine, 4-tert-butylpyridine, 3-acetoxypyridine, 2-phenylpyridine, 4-phenylpyridine, 4-benzoylpyridine, 2-(2-thienyl)pyridine, 2-benzylpyridine, 2-anilinopyridine, 3-pyridinepropanol, 1-(2-pyridyl) piperazine, di-2-pyridyl ketone, ethyl 2-pyridyl acetate, 2-(2-diethylaminoethyl)-pyridine, 4-(2-diethylaminoethyl)pyridine, 2,6-di-tert-butyl pyridine, (S,S)-2,6-bis(4-
- 15 isopropyl-2-oxazolin-2-yl) pyridine, 2,3-pyridine dicarboxylic acid, 2,6-pyridine dicarboxylic acid, 3,5-pyridine dicarboxylic acid, 1,3-di(4-pyridyl)propane, 2,3-di-3-pyridyl-2,3-butanediol, 2,2'-bipyridine, 2,2'-dipyridyl, 4,4'-dimethyl-2,2'-dipyridyl, 3-hydroxypyridine, 2-mercaptopyridine, 2-(2-methylaminoethyl) pyridine, 3-hydroxi picolinamine, 3-hydroxypicolinic acid, 2,2':6',2"-terpyridine, 2-picoline, 6,6'-bi-2-
- 20 picoline, 2,4-lutidine, 2,6-lutidine- α -2,3-diol, 2,6-lutidine 2,4,6-collidine, picolinamide, ethyl picolinate, ethyl isonicotinate, quinoline, 2-phenylquinoline, 8-hydroxyquinoline, 8-acetoxyquinoline, 2-methyl-8-nitroquinoline, 7,8-benzoquinoline, 2-quinolinol, 2-quinolinethiol, quinoline-4-carboxylic acid, 2-phenyl-4-quinoline carboxylic acid, 2,4-hydroxy quinoline monosodium salt, 8-ethoxyquinoline-5-sulfonic acid sodium salt, 8-
- 25 hydroxy-5-nitroquinoline, 4-chloro-7-(trifluoromethyl) quinoline, 8-hydroxyquinoline-5-sulfonic acid monohydrate, 5-nitroquinaldic acid, isoquinoline, isoquinoline-3-carboxylic acid hydrate, 1,4,5-triazanaphthalene, quinaldine, 4-chloroquinaldine, nicotine, isonicotinamine, neocuproine, glycine, *N*-methylglycine, *N,N*-dimethylglycine, glycine hexyl ester, lysine, cystine, α -alanine, arginine, cysteine, β -alanine.
- 30 The most preferred ligands are *trans*-1,2-cyclohexanodiamine and *N*-methylethylenediamine.

The amine ligand is generally employed in an amount in the range of 0.1 to 60 mole percent based on the 2-halo-nitroarene of the compound of the compound of formula II. A useful range is 5 to 15 mole percent of amine ligand based on the 2-halo-nitroarene of the compound of formula II. Most favourably the amine ligand is
5 employed in a ratio of 2 with respect to the copper source.

The reaction step 1 is carried out in the temperature range 60 °C to 150 °C. A useful temperature is from 90 °C to 110 °C, preferably from 70 °C to 90 °C. Generally the reaction is carried out under the exclusion of air and moisture such as under an inert
10 atmosphere like e.g. in an argon or nitrogen atmosphere at atmospheric pressure. The reaction time for step 1 is in the range of 3 to 48 hours (h).

It is possible to filtrate or to isolate the compound of formula IV before reacting it in the second step. It is also possible to perform reaction step 2 without any separation step
15 in the same reaction vessel.

The solvent useful for step 2 or the second solvent in the process of the present invention is an aprotic or protic solvent, wherein the compounds of formula IV or I are soluble or at least partially soluble and compatible with the reaction conditions and
20 involved structures and reagents. Examples of said aprotic or protic solvents are: methanol, ethanol, propanol, acetic acid, methylene chloride, dimethylformamide, tetrahydrofurane, pyridine, *p*-xylene, ethylacetate, benzene, toluene, xylene, mesitylene or acetonitrile. Preferred are methanol, ethanol, acetic acid, methylene chloride, dimethylformamide, pyridine, *p*-xylene and isopropanol. Most preferred is
25 acetic acid.

The reducing reagent useful for the reductive aminocyclisation in step 2 in the process of the present invention can be selected from the following examples, but are not limited to: H₂/Raney-Ni, H₂/Pd-C, H₂/PtO₂, H₂/Ru, NaBH₄/NiCl₂, NaBH₄/FeCl₂,
30 H₃PO₂/Pd-C, Sn/HCl, SnCl₂/HCl, Fe/HOAc, Fe/HCl, FeSO₄/HCl, Fe/FeSO₄, Zn/HCl, Na₂S, and Na₂S₂O₄. Favourable is Fe/HOAc as a reagent for the reductive aminocyclisation.

The reaction step 2 is carried out in the temperature range 80 ° C to 140 °C. A useful temperature is from 110 °C to 120 °C.

The reaction time for step 2 is in the range of 15 min to 120 min.

5

The progress of each reaction step may be monitored by methods known to those skilled in the art, like for example thin layer silica gel chromatography, gas chromatography, nuclear magnetic resonance, infrared spectroscopy, and high pressure liquid chromatography combined with ultraviolet detection or mass spectroscopy. Preferably thin layer silica gel chromatography and high pressure liquid chromatography (HPLC) combined with mass spectroscopy are used.

10

The isolation and purification procedures useful for the compounds obtained by the process of the present invention are well-known to those skilled in the art, like for example filtration through a celite containing cartridge, aqueous work-up, extraction with organic solvents, distillation, crystallisation, chromatography on silica, and high pressure liquid chromatography on normal phase or reversed phase. Preferred methods include, but are not limited to those exemplified.

15

The term alkyl as used herein expressly includes saturated groups as well as unsaturated groups which latter groups contain one or more, for example one, two or three, double bonds and/or triple bonds. All these statements also apply if an alkyl group occurs as a substituent on another residue, for example in an alkyloxy residue, an alkyloxycarbonyl residue or an arylalkyl residue. Examples of „-(C₁-C₈)-alkyl" or „-(C₁-C₈)-alkylene" are alkyl residues containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms are methyl, methylene, ethyl, ethylene, propyl, propylene, butyl, butylene, pentyl, pentylene, hexyl, heptyl or octyl, the n-isomers of all these residues, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tBu, tert-pentyl, sec-butyl, tert-butyl or tert-pentyl. Unsaturated alkyl residues are e.g. alkenyl residues such as vinyl, 1-propenyl, 2-propenyl (= allyl), 2-butenyl, 3-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 5-hexenyl or 1,3-pentadienyl, or alkynyl residues such as ethynyl, 1-propynyl, 2-propynyl

20

25

30

(= propargyl) or 2-butyryl. Alkyl residues can also be unsaturated when they are substituted.

The term “-(C₃-C₈)-cycloalkyl” is understood as cyclic alkyl residues are cycloalkyl residues containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, which can also be substituted and/or unsaturated. Unsaturated cyclic alkyl groups and unsaturated cycloalkyl groups like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.

The term “J1, J2, J3 and J4 are independently from each other selected from carbon or nitrogen atoms and form together with the carbon atoms they are attached to a stable aromatic or heteroaromatic ring” refers to a residue which can be derived from compounds such as benzene pyrazine, pyridazine, pyridine, pyrimidine, triazine or tetrazine.

The term “-(C₆-C₁₄)-aryl” is understood as meaning aromatic hydrocarbon radicals containing from 6 to 14 carbon atoms in the ring. Examples of -(C₆-C₁₄)-aryl radicals are phenyl, naphthyl, for example 1-naphthyl and 2-naphthyl, biphenyl, for example 2-biphenyl, 3-biphenyl and 4-biphenyl, anthryl or fluorenyl. Biphenyl radicals, naphthyl radicals and, in particular, phenyl radicals are preferred aryl radicals.

The term “monocyclic, bicyclic or tricyclic 4- to 15-membered saturated, or partially unsaturated heterocyclic ring containing in addition to the nitrogen atom of the lactam moiety 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen” refers to any monocyclic or bicyclic 4- to 15-membered heterocyclic ring system containing up to 1, 2, 3 or 4 heteroatoms like for example selected from azetidine, azepane, azocane, aza-bicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, azacyclooctanone, azacyclononanone, aza-tricyclo [4.3.1.1*3,8*]undecane, 4,4-dimethyl-3,5-dioxazatricyclo[5.2.1.0*2,6*]-decane, 3,5-dioxazatricyclo-[5.2.1.0*2,6*]decane, 4,4-dimethyl-3,5-dioxazatricyclo [5.2.1.0*2,6*]decan-9-one, azocane-2-one, azonane, 1,4-diazepane, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, imidazoline, imidazolidine, isothiazolidine, isoxazolidine, ketopiperazine, morpholine, [1,4]oxazocane, [1,3]oxazocan-2-one, piperazine, piperidine, pyrazoline, pyrazolidine, 1,2-dihydro-pyridine, pyrrolidine, pyrrolidinone, 2,3-dihydro-1H-pyrrole, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydropyridine, thiadiazine, thiazolidine, thiazoline or thiomorpholine.

The term "-(C₄-C₁₄)-heteroaryl" refers to mono-, di- or tri-ring systems, wherein one or more of the 4 to 14 ring carbon atoms are replaced by heteroatoms such as nitrogen, oxygen or sulfur. Examples are acridinyl, azaindole (1H-pyrrolopyridinyl), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidiny, benzimidazolyl,

- 5 benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnoliny, decahydrochinoliny, 4,5-dihydrooxazoliny, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 3,3-dioxo[1,3,4]oxathiazinyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl,
- 10 furanyl, furazanyl, imidazolidinyl, imidazoliny, imidazolyl, indanyl, 1H-indazolyl, indoliny, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindoliny, isoindolyl, isoquinoliny, isothiazolyl, isothiazolidinyl, isothiazoliny, isoxazolyl, isoxazoliny, isoxazolidinyl, 2-isoxazoliny, ketopiperazinyl, morpholiny, naphthyridiny, octahydroisoquinoliny, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
- 15 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepiny, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazoliny, oxazolyl, oxetanyl, oxocanyl, phenanthridiny, phenanthroliny, phenazinyl, phenothiazinyl, phenoxathiiny, phenoxazinyl, phthalazinyl, piperazinyl, piperidiny, pteridiny, puriny, pyranyl, pyraziny, pyrazolidiny, pyrazoliny, pyrazolyl, pyridazinyl,
- 20 pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridiny, pyridyl, pyrimidiny, pyrrolidinyl, pyrrolidinonyl, pyrroliny, 2H-pyrrolyl, pyrrolyl, quinazoliny, quinoliny, 4H-quinoliziny, quinoxaliny, quinuclidiny, tetrahydrofuranyl, tetrahydroisoquinoliny, tetrahydroquinoliny, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridiny, tetrahydrothiophenyl, tetraziny, tetrazolyl, 6H-1,2,5-thiadiaziny, 1,2,3-thiadiazolyl,
- 25 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiaziny, 1,3-thiaziny, 1,4-thiaziny, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazoliny, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholiny, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triaziny, 1,2,4-triaziny, 1,3,5-triaziny, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl.
- 30 The term "a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms" refer to structures of heterocycles, which can be derived from compounds such as

azepine, azetidine, aziridine, azirine, 1,4 diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxetan, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole.

The 3- to 7- membered monocyclic group may be bonded via any ring carbon atom, and in the case of nitrogen heterocycles via any suitable ring nitrogen atom. Thus, for example, a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, a pyrrolidinyl residue can be pyrrolidin-1-yl (= pyrrolidino), pyrrolidin-2-yl or pyrrolidin-3-yl, a pyridinyl residue can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, a piperidinyl residue can be piperidin-1-yl (= piperidino), piperidin-2-yl, piperidin-3-yl or piperidin-4-yl. Furyl can be 2-furyl or 3-furyl, thienyl can be 2-thienyl or 3-thienyl, imidazolyl can be imidazol-1-yl, imidazol-2-yl, imidazol-4-yl or imidazol-5-yl, 1,3-oxazolyl can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl or 1,3-oxazol-5-yl, 1,3-thiazolyl can be 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,3-thiazol-5-yl, pyrimidinyl can be pyrimidin-2-yl, pyrimidin-4-yl (= 6-pyrimidinyl) or 5-pyrimidinyl, piperazinyl can be piperazin-1-yl (= piperazin-4-yl = piperazino) or piperazin-2-yl.

The term "R1 and R2, R2 and R3 or R3 and R4 form together with the atoms which they are attached to a 5- or 8-membered ring, containing up to 0, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen" refers to residues which can be derived from compounds such as azepine, azirine, azocane, azocane-2-one, cycloheptyl, cyclohexyl, cyclooctane, cyclooctene, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,2]diazocan-3-one, [1,3]diazocan-2-one, [1,4]diazocane, dioxazine, dioxazole, [1,4]dioxocane, 1,3-dioxolane, dioxole, 1,3-dioxolene, furan, imidazole, imidazolidine, imidazoline, isothiazole, isothiazolidine, isothiazoline,

isothiazole, isoxazole, isoxazolidine, isoxazoline, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, [1,4]oxazocane, [1,3]oxazocan-2-one, oxocane, oxocan-2-one, oxazole, piperidine, piperazine, phenyl, pyridazine, pyridine, pyrimidine, pyran, pyrazine, pyrazole, pyrazolepyrrole, pyrazolidine, pyrazoline, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, 5,6,7,8-tetrahydro-1*H*-azocin-2-one, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, thiazole, 1,3-thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole.

The fact that many of the before-listed names of heterocycles are the chemical names of unsaturated or aromatic ring systems does not imply that the, 4- to 14-membered mono- or polycyclic group could only be derived from the respective unsaturated ring system. The names here only serve to describe the ring system with respect to ring size and the number of the heteroatoms and their relative positions. As explained above, the 4- to 14-membered mono- or polycyclic group can be saturated or partially unsaturated or aromatic, and can thus be derived not only from the before-listed heterocycles themselves but also from all their partially or completely hydrogenated analogues and also from their more highly unsaturated analogues if applicable. As examples of completely or partially hydrogenated analogues of the before-listed heterocycles from which this group may be derived the following may be mentioned: pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline or 1,2,3,4-tetrahydroisoquinoline.

The term “-(C₁-C₃)-fluoroalkyl” is a partial or totally fluorinated alkyl-residue, which can be derived from residues such as -CF₃, -CHF₂, -CH₂F, -CHF-CF₃, -CHF-CHF₂, -CHF-CH₂F, -CH₂-CF₃, -CH₂-CHF₂, -CH₂-CH₂F, -CF₂-CF₃, -CF₂-CHF₂, -CF₂-CH₂F, -CH₂-CHF-CF₃, -CH₂-CHF-CHF₂, -CH₂-CHF-CH₂F, -CH₂-CH₂-CF₃,

-CH₂-CH₂-CHF₂, -CH₂-CH₂-CH₂F, -CH₂-CF₂-CF₃, -CH₂-CF₂-CHF₂,
 -CH₂-CF₂-CH₂F, -CHF-CHF-CF₃, -CHF-CHF-CHF₂, -CHF-CHF-CH₂F,
 -CHF-CH₂-CF₃, -CHF-CH₂-CHF₂, -CHF-CH₂-CH₂F, -CHF-CF₂-CF₃,
 -CHF-CF₂-CHF₂, -CHF-CF₂-CH₂F, -CF₂-CHF-CF₃, -CF₂-CHF-CHF₂,
 5 -CF₂-CHF-CH₂F, -CF₂-CH₂-CF₃, -CF₂-CH₂-CHF₂, -CF₂-CH₂-CH₂F,
 -CF₂-CF₂-CF₃, -CF₂-CF₂-CHF₂ or -CF₂-CF₂-CH₂F.

Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, particularly preferably chlorine or bromine.

The term "triflate" refers to trifluoro-methanesulfonic acid ester or
 10 trifluoromethanesulfonate.

The term "nonaflate" refers to 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanesulfonic acid ester or 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanesulfonate.

The term "at least one of R₁, R₂, R₃ or R₄ are absent in case one or more of J₁, J₂, J₃ or J₄ are nitrogen atom," refers to a residue wherein the nitrogen atom is not
 15 substituted by any residue, e.g. in case J₁ is nitrogen atom and J₂, J₃ and J₄ are each a carbon atom and R₄ is absent and R₁, R₂ and R₃ are each a hydrogen atom the residue pyridine is formed. If R₁, R₂ and R₃ are not each a hydrogen atom but one of the residues specified under b) to x) then a substituted pyridine residue is formed. In case J₁ and J₂ are each a nitrogen atom and J₃ and J₄ are each a carbon atom and
 20 R₄ and R₃ are absent and R₁ and R₂ are each a hydrogen atom the residue pyridazine is formed. If R₁ and R₂ are not each a hydrogen atom but one of the residues specified under b) to x) then a substituted pyridazine residue is formed.

Optically active carbon atoms present in the compounds of the formula (I) can
 25 independently of each other have R configuration or S configuration. The compounds of the formula (I) can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers and/or diastereomers, for example in the form of racemates. The present invention relates to pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers. The
 30 invention comprises mixtures of two or of more than two stereoisomers of the formula (I), and it comprises all ratios of the stereoisomers in the mixtures. In case the

compounds of the formula (I) can be present as E isomers or Z isomers (or cis isomers or trans isomers) the invention relates both to pure E isomers and pure Z isomers and to E/Z mixtures in all ratios. The invention also comprises all tautomeric forms of the compounds of the formula (I).

- 5 Diastereomers, including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by customary methods, for example by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases. Stereochemically uniform compounds of the formula (I) can also
10 be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.

- The starting materials or building blocks for use in the general synthetic procedures that can be applied in the preparation of the compounds of formula (I) are readily
15 available to one of ordinary skill in the art. In many cases they are commercially available or have been described in the literature. Otherwise they can be prepared from readily available precursor compounds analogously to procedures described in the literature, or by procedures or analogously to procedures described in this application.

- 20 Further, in order to obtain the desired substituents in the benzene nucleus and in the heterocyclic nucleus of the benzimidazole or azabenzimidazole ring system in the formula (I), the functional groups introduced into the ring system during the benzimidazole or azabenzimidazole synthesis can be chemically modified. For example, benzimidazoles carrying a hydrogen atom in the 7-position can also be
25 obtained by oxidation of 7-methyl benzimidazole to the benzimidazole-7-carboxylic acid and subsequent decarboxylation or from benzimidazoles carrying an ester group in the respective position. Carboxylic acid groups and acetic acid groups in the 7-position can be converted into their homologues by usual reactions for chain elongation of carboxylic acids.
- 30 Especially the groups present in the benzimidazole or azabenzimidazole ring system can be modified by a variety of reactions and thus the desired residues R1, R2, R3, R4 and R5 be obtained. For example, nitro groups can be reduced to amino group with

under the described reaction conditions or by various reducing agents, such as sulfides, dithionites, complex hydrides or by catalytic hydrogenation. A reduction of a nitro group may also be carried out at a later stage of the synthesis of a compound of the formula (I), and a reduction of a nitro group to an amino group may also occur
5 simultaneously with the reaction performed on another functional group, for example when reacting a group like a cyano group with hydrogen sulfide or when hydrogenating a group. Ester groups present in the benzene nucleus can be hydrolyzed to the corresponding carboxylic acids, which after activation can then be reacted with amines or alcohols under standard conditions. Ether groups present at the benzene nucleus,
10 for example benzyloxy groups or other easily cleavable ether groups, can be cleaved to give hydroxyl groups which then can be reacted with a variety of agents, for example etherification agents or activating agents allowing replacement of the hydroxyl group by other groups. Sulfur-containing groups can be reacted analogously.

15 Due to the fact that in the present case the functional groups are attached to an benzimidazole or azabenzimidazole ring it may in certain cases become necessary to specifically adapt reaction conditions or to choose specific reagents from a variety of reagents that can in principle be employed into a conversion reaction, or otherwise to take specific measures for achieving a desired conversion, for example to use
20 protection group techniques. However, finding out suitable reaction variants and reaction conditions in such cases does not cause any problems for one skilled in the art.

In the course of the preparation of the compounds of the formula I it can generally be
25 advantageous or necessary to introduce functional groups which reduce or prevent undesired reactions or side reactions in the respective synthesis step, in the form of precursor groups which are later converted into the desired functional groups, or to temporarily block functional groups by a protective group strategy suited to the synthesis problem. Such strategies are well known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, Wiley, 1991, or
30 P. Kocienski, Protecting Groups, Thieme 1994). As example of a precursor group cyano groups may be mentioned which can in a later step be transformed into

carboxylic acid derivatives or by reduction into aminomethyl groups. Protective groups can also have the meaning of a solid phase, and cleavage from the solid phase stands for the removal of the protective group. The use of such techniques is known to those skilled in the art (Burgess K (Ed.) Solid Phase Organic Synthesis, New York: Wiley, 2000). For example, a phenolic hydroxy group can be attached to a trityl-polystyrene resin, which serves as a protecting group, and the molecule is cleaved from this resin by treatment with trifluoroacetic acid (TFA) at a later stage of the synthesis.

In the course of the synthesis the employment of microwave assistance for speeding-up, facilitating or enabling reactions may be beneficial or even required in many cases.

Some reactions are for example described by J. L. Kristenansky, I. Cotteril, Curr. Opin. Drug. Disc. & Development., 4(2000), 454; Lidstrom, J. Tierney, B. Wathey, J. Westman, Tetrahedron, 57(2001), 9225; M. Larhed, A. Hallberg, Drug Discovery Today, 8 (2001) 406; S. Caddick, Tetrahedron, 51 (1995) 10403.

Physiologically tolerable salts of the compounds of formula I are nontoxic salts that are physiologically acceptable, in particular, pharmaceutically utilizable salts. Such salts of compounds of formula I containing acidic groups, for example, a carboxyl group (COOH), include, for example, alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts, magnesium salts and calcium salts, as well as salts with physiologically tolerable quaternary ammonium ions, such as tetramethylammonium or tetraethylammonium, and acid addition salts with ammonia and physiologically tolerable organic amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine. Basic groups contained in the compounds of formula I, for example, amino groups or guanidino groups, form acid addition salts, for example, with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formula I which simultaneously contain a basic group and an acidic group, for example, a guanidino group and a carboxyl group, can also be present as zwitterions (betaines) which are likewise included in the scope of the present invention.

Salts of compounds of formula I can be obtained by customary methods known to those skilled in the art, for example, by combining a compound of the formula I with an inorganic or organic acid or base in a solvent or dispersant, or from other salts by cation exchange or anion exchange. The present invention also includes all salts of the
5 compounds of formula I which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of formula I or as starting materials for the preparation of physiologically tolerable salts.

10 A further aspect of the invention is the use of a compound of the formula I as prepared by the process according to the invention for the production of pharmaceuticals, diagnostic agents, liquid crystals, polymers, herbicides, fungicides, nematocides, parasiticides, insecticides, acaricides and arthropodocides.

15 Preferred methods include, but are not limited to those described in the examples. Furthermore, the compounds of the formula I can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.

20

The general synthetic sequences for preparing the compounds useful in the present invention are outlined in the examples given below. Both an explanation of, and the actual procedure for, the various aspects of the present invention are described where appropriate. The following examples are intended to be merely illustrative of the
25 present invention, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known variations of the conditions and processes described in the examples can be used to synthesize the compounds of the present invention.

30


Examples

When in the final step of the synthesis of a compound an acid such as trifluoroacetic acid or acetic acid was used, for example when trifluoroacetic acid was employed to remove a tBu group or when a compound was purified by chromatography using an


- 5 eluent which contained such an acid, in some cases, depending on the work-up procedure, for example the details of a freeze-drying process, the compound was obtained partially or completely in the form of a salt of the acid used, for example in the form of the acetic acid salt or trifluoroacetic acid salt or hydrochloric acid salt.

10 Abbreviations used:


2,2'-bis(diphenylphosphino)-1,1'-binaphthalene	BINAP
Calculated	cal
dibenzylidenacetone	dba
Dimethylsulfoxide	DMSO
15 1,1'-Bis(diphenylphosphino)ferrocene	DPPF
Fast atom bombardment	FAB
Acetic acid	HOAc
High pressure liquid chromatography	HPLC
Liquid chromatography with mass spectrometry	LC-MS
20 Melting point	mp
Room temperature 20 °C to 25 °C	RT
tert-Butyl	tBu
Trifluoroacetic acid	TFA
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene	Xantphos

Example 1: 2,3-Dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole

(Method A): 1-Iodo-2-nitrobenzene (125 mg, 0.5 mmol), pyrrolidin-2-one (51 mg, 0.6 mmol), palladium trifluoroacetate (13 mg, 0.04 mmol), BINAP (24 mg, 0.08 mmol), and cesium carbonate (212 mg, 0.7 mmol) were placed in a reaction tube, which was the
5 purged with dry argon. Dry toluene (3 mL), was added, and the mixture was heated at 80 °C for 18 h. After cooling to RT, 10 mL of glacial acetic acid and powder iron (279 mg, 5 mmol) were added and the crude was refluxed for 30 min. The acid was removed under reduced pressure and the residue was suspended in saturated sodium
10 bicarbonate solution and extracted with ethyl acetate. The obtained crude was purified by preparative HPLC, affording the title compound as colorless solid (58 mg, 73%). mp 86-88°C. ¹H NMR δ 2.75 (t, *J* = 6.9 Hz, 2 H), 3.24-3.33 (m, 2 H), 4.33 (t, *J* = 7.2 Hz, 2 H), 7.46-7.50 (m, 2 H), 7.74-7.86 (m, 2 H); ¹³C NMR δ 23.7, 25.3, 45.3, 112.7, 115.1, 124.7, 125.0, 128.9, 136.6, 157.0. HRMS (FAB): calc. for C₁₀H₁₁N₂ [*M*+*H*⁺]: 159.0922; found: 159.0919.
15

Example 2: 7-methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole


Method A applied to 2-Chloro-4-methyl-1-nitrobenzene (86 mg, 0.5 mmol) and
20 pyrrolidin-2-one (51 mg, 0.6 mmol) afforded the title compound as a viscous oil (72 mg, 84%). ¹H NMR (DMSO) δ 2.73-2.82 (m, 2 H), 3.32 (t, *J* = 7.1 Hz), 4.35 (t, *J* = 7.2 Hz, 2 H), 7.33 (d, *J* = 8.3 Hz, 1 H), 7.57 (s, 1 H), 7.69 (d, *J* = 8.3 Hz, 1 H); ¹³C NMR δ 21.0, 23.8, 25.3, 45.6, 112.5, 114.3, 126.4, 127.1, 135.5, 136.1, 157.8.

25 Example 3: 6-methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole

Method A applied to 1-Chloro-4-methyl-2-nitrobenzene (86 mg, 0.5 mmol) and
pyrrolidin-2-one (51 mg, 0.6 mmol) afforded the title compound as a viscous oil (74 mg,


86%). ^1H NMR (DMSO) δ 2.55-2.63 (m, 2 H), 2.76 (s, 3 H), 3.21 (t, $J = 7.7$ Hz, 2 H), 3.85 (s, 3 H), 4.26 (t, $J = 7.1$ Hz, 2 H), 7.56 (d, $J = 8.6$ Hz, 1 H), 7.85 (d, $J = 8.6$ Hz, 1 H); ^{13}C NMR δ 21.0, 23.7, 25.2, 45.3, 112.4, 114.5, 126.5, 129.2, 134.8, 137.8, 157.2.

5 Example 4: 7-methoxy-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole




Method A applied to 1-Iodo-4-methoxy-2-nitrobenzene (140 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol) afforded the title compound as a viscous oil (84 mg, 89%). ^1H NMR (DMSO) δ 2.74 (t, $J = 6.9$ Hz, 2 H), 3.24-3.32 (m, 2 H), 3.86 (s, 3 H), 4.32 (t, $J = 7.1$ Hz, 2 H), 7.09 (d, $J = 9.1$ Hz, 1 H), 7.44 (d, $J = 9.1$ Hz, 1 H), 7.58 (s, 1 H); ^{13}C NMR δ 23.6, 25.3, 45.4, 55.9, 96.0, 114.6, 115.6, 128.7, 129.6, 157.4, 158.2.

Example 5: 5-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole-6-carboxylic acid methyl ester



Method A applied to 4-Bromo-2-methyl-3-nitrobenzoic acid methyl ester (137 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol) afforded the title compound as a viscous oil (89 mg, 77%). ^1H NMR (DMSO) δ 2.55-2.63 (m, 2 H), 2.76 (s, 3 H), 3.21 (t, $J = 7.7$ Hz, 2 H), 3.85 (s, 3 H), 4.26 (t, $J = 7.1$ Hz, 2 H), 7.56 (d, $J = 8.6$ Hz, 1 H), 7.85 (d, $J = 8.6$ Hz, 1 H); ^{13}C NMR δ 14.7, 23.4, 25.4, 44.5, 51.9, 99.1, 109.0, 124.0, 125.6, 129.2, 131.6, 161.6, 167.1.


Example 6: 2-Methoxy-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine



Method A applied to 2-Chloro-6-methoxy-3-nitropyridine (94 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol) afforded the title compound as a viscous oil (72 mg,


76%). ^1H NMR (DMSO) δ 2.68 (p, J = 6.9 Hz, 2 H), 3.23 (t, J = 6.9 Hz, 2 H), 3.91 (s, 3 H), 4.22 (t, J = 6.9 Hz), 6.82 (d, J = 8.6 Hz, 1 H), 8.02 (d, J = 8.6 Hz, 1 H).

Example 7: 2,6-Dimethyl-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine




Method A applied to 2-Chloro-6-methyl-3-nitropyridine (94 mg, 0.5 mmol) and 3-methylpyrrolidin-2-one (59 mg, 0.6 mmol) afforded the title compound as a viscous oil (24 mg, 26%). ^1H NMR (DMSO) δ 1.42 (d, J = 6.9 Hz, 3 H), 2.22-2.32 (m, 1 H), 2.55 (s, 3 H), 2.86-2.97 (m, 1 H), 3.53-2.61 (m, 1 H), 4.12-4.38 (m, 2 H), 7.27 (d, J = 8.0 Hz, 1 H), 7.99 (d, J = 8.0 Hz, 1 H).

Example 8:



Method A applied to 2-Chloro-6-methyl-3-nitropyridine (94 mg, 0.5 mmol) and (1*S*,2*R*,6*S*,7*R*)-4,4-dimethyl-3,5-dioxa-8-azatricyclo[5.2.1.0*2,6*]decan-9-one (110 mg, 0.6 mmol) afforded the title compound as a viscous oil (126 mg, 88%). ^1H NMR (DMSO) δ 1.23 (s, 3 H), 1.51 (s, 3 H), 2.47-2.57 (m, 2 H), 2.53 (s, 3 H), 3.62 (s, 3 H), 4.23 (d, J = 4.8 Hz, 1 H), 4.35 (d, J = 4.8 Hz, 1 H), 7.12 (d, J = 7.9 Hz, 1 H), 7.88 (d, J = 7.9 Hz, 1 H).


Example 9: 1,2,3,4-Tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine



Method A applied to 1-Iodo-2-nitrobenzene (125 mg, 0.5 mmol) and piperidin-2-one (59 mg, 0.6 mmol) afforded the title compound as pale yellow solid (65 mg, 75%). mp 104-106°C. ^1H NMR (DMSO) δ 1.98-2.07 (m, 4 H), 3.16-3.23 (m, 2 H), 4.30 (t, J = 6.9 Hz, 2 H), 7.51-7.56 (m, 2 H), 7.75-7.92 (m, 2 H); ^{13}C NMR δ 17.7, 20.5, 22.3, 43.0,

112.3, 114.2, 124.7, 125.6, 131.5, 151.8, 156.6. HRMS (FAB): cal for $C_{11}H_{13}N_2$ $[M+H]^+$: 173.1079; found: 173.1071.

Example 10: 3,9-Dimethyl-6,7,8,9-tetrahydro-dipyrido[1,2-a;3',2'-d]imidazole




5

Method A applied to 2-Chloro-5-methyl-3-nitropyridine (86 mg, 0.5 mmol) and 3-methylpiperidin-2-one (68 mg, 0.6 mmol) afforded the title compound as viscous oil (60 mg, 60%). 1H NMR (DMSO) δ 1.49 (s, 3 H), 1.51 (s, 3 H), 1.92-2.23 (m, 4 H), 3.04-3.20 (m, 2 H), 4.75-4.83 (m, 1 H), 7.98 (s, 1 H), 8.37 (s, 1 H).

10


Example 11: 7-Chloro-4,4-diphenyl-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-a]pyridine



Method A applied to 2,5-Dichloronitrobenzene (96 mg, 0.5 mmol) and 3,3-diphenylpiperidin-2-one (151 mg, 0.6 mmol) afforded the title compound as a brown solid (63 mg, 35%). 1H NMR (DMSO) δ 1.91-2.02 (m, 2 H), 2.76-2.81 (m, 2 H), 4.37 (t, J = 6.2 Hz, 2 H), 7.12-7.49 (m, 11 H), 7.64 (d, J = 8.8 Hz, 1 H), 7.69 (s, 1 H).

15

Example 12: Dimethyl-(S)-7,8,9,10-tetrahydro-6H-benzo[4,5]imidazo[1,2-a]azepin-6-yl-amine




20

Method A applied to 1-Iodo-2-nitrobenzene (125 mg, 0.5 mmol) and (S)-3-dimethylaminoazepan-2-one (94 mg, 0.6 mmol) afforded the title compound as a pale yellow solid (84 mg, 73%). mp 164-166 °C. 1H NMR (DMSO) δ 1.44-2.46 (m, 6 H), 3.03 (s, 6 H), 3.96 (dd, J = 11.9, 11.6 Hz, 1 H), 4.63 (dd, J = 14.5, 4.7 Hz, 1 H), 5.03 (d, J = 10.4 Hz, 1 H), 7.26 (t, J = 7.3 Hz, 1 H), 7.38 (t, J = 7.3 Hz, 1 H), 7.52-7.72 (m, 5 H),

25


7.79 (d, $J = 7.8$ Hz, 1 H); ^{13}C NMR δ 25.2, 26.2, 27.0, 40.6, 43.5, 62.4, 110.3, 118.8, 122.0, 122.8, 135.3, 140.6, 151.1. HRMS (FAB): cal. for $\text{C}_{14}\text{H}_{20}\text{N}_3$ $[\text{M}+\text{H}^+]$: 230.1657; found: 230.1648.

5 Example 13: 3-Methyl-5,6,7,8,9,10-hexahydro-4,4b,11-triaza-cycloocta[a]indene




Method A applied to 2-Chloro-6-methyl-3-nitropyridine (94 mg, 0.5 mmol) and 2-azacyclooctanone (76 mg, 0.6 mmol) afforded the title compound as a viscous oil (74 mg, 69%). ^1H NMR (DMSO) δ 1.22-1.88 (m, 8 H), 2.62 (s, 3 H), 3.19 (t, $J = 6.5$ Hz, 2 H), 4.51 (t, $J = 5.7$ Hz, 2 H), 7.38 (d, $J = 8.0$ Hz, 1 H), 8.09 (d, $J = 8.0$ Hz, 1 H).

Example 14: 2-Methyl-6,7,8,9,10,11-hexahydro-5H-4,4b,12-triaza-cyclonona[a]indene




Method A applied to 2-Chloro-5-methyl-3-nitropyridine (86 mg, 0.5 mmol) and 2-azacyclononanone (85 mg, 0.6 mmol) afforded the title compound as a viscous oil (40 mg, 35%). ^1H NMR (DMSO) δ 1.18-1.96 (m, 10 H), 2.48 (s, 3 H), 3.18 (t, $J = 6.0$ Hz, 2 H), 4.54 (t, $J = 6.5$ Hz, 2 H), 7.99 (s, 1 H), 8.36 (s, 1 H).

Example 15: 3-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-a;3',2'-d]imidazole.




Method A applied to 2-Chloro-5-methyl-3-nitropyridine (86 mg, 0.5 mmol) and 5,5-diphenyl-piperidin-2-one (151 mg, 0.6 mmol) afforded the title compound as solid (93 mg, 55%). ^1H NMR (DMSO) δ 2.48-2.54 (m, 4 H), 2.93 (s, 3 H), 4.87 (s, 2 H), 7.18-7.34 (m, 10 H), 7.98 (s, 1 H), 8.41 (s, 1 H).

Example 16:



Method A applied to 1,2-iodonitrobenzene (125 mg, 0.5 mmol) and (1*R*,3*R*,6*S*,8*S*)-4-Aza-tricyclo[4.3.1.1*3,8*]undecan-5-one (99 mg, 0.6 mmol) afforded the title

- 5 compound as a solid (99 mg, 83%). ¹H NMR (DMSO) δ 1.84-2.23 (m, 12 H), 3.54-3.57 (m, 1 H), 5.17 (s, 1 H), 7.53-7.58 (m, 2 H), 7.80 (d, *J* = 7.2 Hz, 1 H), 7.98 (d, *J* = 7.2 Hz, 1 H).

Example 17: 2,3-Dihydro-1*H*-benzo[*d*]pyrrolo[1,2-*a*]imidazole.

10

A reaction tube containing 2-iodonitrobenzene (125 mg, 0.5 mmol), pyrrolidin-2-one (51 mg, 0.6 mmol), CuI (4.8 mg, 0.025 mmol), *N*-methylethylenediamine (4.4 μL, 0.05 mmol), potassium phosphate (212 mg, 1 mmol) in dry toluene (3 mL) was purged with dry argon for 3 min. Then the mixture was heated at 100 °C for 18 h. (In other

- 15 reactions *trans*-1,2-cyclohexanodiamine was used instead of *N*-

methylethylenediamine). After cooling, the reaction was hydrolyzed with 3 mL of water and filtered through a Varian cartridge Chem Elut 12198007, rinsing with ethyl acetate.


The crude mixture was dissolved in 10 mL of glacial acetic acid and refluxed for 30 min in the presence of iron powder (279 mg, 5 mmol). The acid was removed under

- 20 reduced pressure and the residue was suspended in saturated sodium bicarbonate solution and extracted with ethyl acetate. The obtained crude was purified by

preparative HPLC, affording the title compound as a colorless solid (58 mg, 73%). mp 86-88°C. ¹H NMR δ 2.75 (t, *J* = 6.9 Hz, 2 H), 3.24-3.33 (m, 2 H), 4.33 (t, *J* = 7.2 Hz, 2 H), 7.46-7.50 (m, 2 H), 7.74-7.86 (m, 2 H); ¹³C NMR δ 23.7, 25.3, 45.3, 112.7, 115.1,


- 25 124.7, 125.0, 128.9, 136.6, 157.0. HRMS (FAB): cal. for C₁₀H₁₁N₂ [*M*+*H*⁺]: 159.0922; found: 159.0919.

Example 18: 7-methyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole




The same method was applied to 2-Chloro-4-methyl-1-nitrobenzene (86 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol), using *N*-methylethylenediamine as ligand (4.4 μ L, 0.05 mmol) and afforded the title compound as a viscous oil (72 mg, 84%). ^1H NMR (DMSO) δ 2.73-2.82 (m, 2 H), 3.32 (t, J = 7.1 Hz), 4.35 (t, J = 7.2 Hz, 2 H), 7.33 (d, J = 8.3 Hz, 1 H), 7.57 (s, 1 H), 7.69 (d, J = 8.3 Hz, 1 H); ^{13}C NMR δ 21.0, 23.8, 25.3, 45.6, 112.5, 114.3, 126.4, 127.1, 135.5, 136.1, 157.8.

10 Example 19: 6-methyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole




The same method was applied to 1-Chloro-4-methyl-2-nitrobenzene (86 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol), using *N*-methylethylenediamine (4.4 μ L, 0.05 mmol) as ligand, and afforded the title compound as a viscous oil (74 mg, 86%). ^1H NMR (DMSO) δ 2.55-2.63 (m, 2 H), 2.76 (s, 3 H), 3.21 (t, J = 7.7 Hz, 2 H), 3.85 (s, 3 H), 4.26 (t, J = 7.1 Hz, 2 H), 7.56 (d, J = 8.6 Hz, 1 H), 7.85 (d, J = 8.6 Hz, 1 H); ^{13}C NMR δ 21.0, 23.7, 25.2, 45.3, 112.4, 114.5, 126.5, 129.2, 134.8, 137.8, 157.2.

Example 20: 7-methoxy-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole.




The same method was applied to 1-Iodo-4-methoxy-2-nitrobenzene (140 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol), using *N*-methylethylenediamine (4.4 μ L, 0.05 mmol) as ligand, and afforded the title compound as a viscous oil (84 mg, 89%). ^1H NMR (DMSO) δ 2.74 (t, J = 6.9 Hz, 2 H), 3.24-3.32 (m, 2 H), 3.86 (s, 3 H), 4.32 (t, J = 7.1 Hz, 2 H), 7.09 (d, J = 9.1 Hz, 1 H), 7.44 (d, J = 9.1 Hz, 1 H), 7.58 (s, 1 H); ^{13}C NMR δ 23.6, 25.3, 45.4, 55.9, 96.0, 114.6, 115.6, 128.7, 129.6, 157.4, 158.2.

Example 21: 5-Methyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole-6-carboxylic acid methyl ester.




The same method was applied to 4-Bromo-2-methyl-3-nitrobenzoic acid methyl ester (137 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol), using *N*-methylethylenediamine (4.4 μ L, 0.05 mmol) as ligand, and afforded the title compound as a viscous oil (89 mg, 77%). ^1H NMR (DMSO) δ 2.55-2.63 (m, 2 H), 2.76 (s, 3 H), 3.21 (t, J = 7.7 Hz, 2 H), 3.85 (s, 3 H), 4.26 (t, J = 7.1 Hz, 2 H), 7.56 (d, J = 8.6 Hz, 1 H), 7.85 (d, J = 8.6 Hz, 1 H); ^{13}C NMR δ 14.7, 23.4, 25.4, 44.5, 51.9, 99.1, 109.0, 124.0, 125.6, 129.2, 131.6, 161.6, 167.1.

Example 22: 2-Methoxy-7,8-dihydro-6H-pyrrolo[2',1':2,3]imidazo[4,5-b]pyridine




The same method was applied to 2-Chloro-6-methoxy-3-nitropyridine (94 mg, 0.5 mmol) and pyrrolidin-2-one (51 mg, 0.6 mmol), using *trans*-1,2-cyclohexanodiamine as ligand (6 μ L, 0.05 mmol), and afforded the title compound as a viscous oil (28 mg, 30%). ^1H NMR (DMSO) δ 2.68 (p, J = 6.9 Hz, 2 H), 3.23 (t, J = 6.9 Hz, 2 H), 3.91 (s, 3 H), 4.22 (t, J = 6.9 Hz), 6.82 (d, J = 8.6 Hz, 1 H), 8.02 (d, J = 8.6 Hz, 1 H).

Example 23: 2,6-Dimethyl-7,8-dihydro-6H-pyrrolo[2',1':2,3]imidazo[4,5-b]pyridine




The same method was applied to 2-Bromo-6-methyl-3-nitropyridine (109 mg, 0.5 mmol) and 3-methylpyrrolidin-2-one (59 mg, 0.6 mmol), using *trans*-1,2-cyclohexanodiamine as ligand (6 μ L, 0.05 mmol), and afforded the title compound as a viscous oil (77 mg, 83%). ^1H NMR (DMSO) δ 1.42 (d, J = 6.9 Hz, 3 H), 2.22-2.32 (m, 1 H), 2.55 (s, 3 H), 2.86-2.97 (m, 1 H), 3.53-2.61 (m, 1 H), 4.12-4.38 (m, 2 H), 7.27 (d, J = 8.0 Hz, 1 H), 7.99 (d, J = 8.0 Hz, 1 H).


Example 24:



The same method was applied to 2-Bromo-3-nitropyridine (101 mg, 0.5 mmol) and (1*S*,2*R*,6*S*,7*R*)-4,4-dimethyl-3,5-dioxa-8-azatricyclo[5.2.1.0^{2,6}]decan-9-one (110 mg, 0.6 mmol), using *trans*-1,2-cyclohexanodiamine as ligand (6 μ L, 0.05 mmol), and afforded the title compound as a viscous oil (57 mg, 44%). ¹H NMR (DMSO) δ 1.23 (s, 3 H), 1.48 (s, 3 H), 2.47-2.57 (m, 2 H), 2.53 (s, 3 H), 3.64 (s, 3 H), 4.22 (d, J = 4.8 Hz, 1 H), 4.34 (d, J = 4.8 Hz, 1 H), 7.22 (dd, J = 7.9, 5.2 Hz, 1 H), 7.99 (d, J = 7.9 Hz, 1 H), 8.27 (d, J = 5.2 Hz, 1 H).

Example 25: 1,2,3,4-Tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine


The same method was applied to 1-Iodo-2-nitrobenzene (125 mg, 0.5 mmol) and piperidin-2-one (59 mg, 0.6 mmol), using *N*-methylethylenediamine (4.4 μ L, 0.05 mmol) as ligand, and afforded the title compound as pale yellow solid (65 mg, 75%). mp 104-106°C. ¹H NMR (DMSO) δ 1.98-2.07 (m, 4 H), 3.16-3.23 (m, 2 H), 4.30 (t, J = 6.9 Hz, 2 H), 7.51-7.56 (m, 2 H), 7.75-7.92 (m, 2 H); ¹³C NMR δ 17.7, 20.5, 22.3, 43.0, 112.3, 114.2, 124.7, 125.6, 131.5, 151.8, 156.6. HRMS (FAB): cal. for C₁₁H₁₃N₂ [M+H⁺]: 173.1079; found: 173.1071.

Example 26: 2-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*:3',2'-*d*]imidazole

The same method was applied to 2-Bromo-6-methyl-3-nitropyridine (86 mg, 0.5 mmol) and 5,5-diphenylpiperidin-2-one (151 mg, 0.6 mmol), using *trans*-1,2-cyclohexanodiamine as ligand (6 μ L, 0.05 mmol), and afforded the title compound as solid (87 mg,

51%). ^1H NMR (DMSO) δ 2.68 (s, 3 H), 2.88-2.97 (m, 4 H), 4.82 (s, 2 H), 7.21-7.33 (m, 10 H), 7.38 (d, J = 8.2 Hz, 1 H), 8.04 (d, J = 8.2 Hz, 1 H).

Example 27: 5,6,7,8,9,10-Hexahydro-1,4b,11-triaza-cyclooct[a]indene




5

The same method was applied to 3-Bromo-2-nitropyridine (102 mg, 0.5 mmol) and 2-azacyclooctanone (76 mg, 0.6 mmol), using *trans*-1,2-cyclohexanodiamine as ligand (6 μL , 0.05 mmol), and afforded the title compound as a viscous oil (20 mg, 20%). ^1H NMR (DMSO) δ 1.16-1.25 (m, 2 H), 1.41-1.52 (m, 2 H), 1.82-1.91 (m, 4 H), 3.26 (t, J = 6.2 Hz, 2 H), 4.61 (t, J = 6.1 Hz, 2 H), 7.59 (dd, J = 8.2, 5.5 Hz, 1 H), 8.48 (d, J = 8.2 Hz, 1 H), 8.62 (d, J = 5.5 Hz, 1 H).

10

Example 28: 3-Methoxy-6,7,8,9,10,11-hexahydro-5*H*-4b,12-diaza-cyclonon[a]indene.




15

The same method was applied to 3-Iodo-4-nitroanisole (140 mg, 0.5 mmol) and 2-azacyclononanone (85 mg, 0.6 mmol), using *N*-methylethylenediamine (4.4 μL , 0.05 mmol) as ligand, and afforded the title compound as brown solid (70 mg, 57%). ^1H NMR (DMSO) δ 1.18-1.96 (m, 10 H), 3.23 (t, J = 6.4 Hz, 2 H), 3.88 (s, 3 H), 4.61 (t, J = 6.1 Hz, 2 H), 7.17 (dd, J = 8.6, 3.1 Hz, 1 H), 7.52 (d, J = 3.1 Hz, 1 H), 7.73 (d, J = 8.6 Hz, 1 H).

20

Claims

1. A process for preparing a compound of formula I



- 5 and/or all stereoisomeric forms of the compound of formula I, and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of formula I, wherein
- J1, J2, J3 and J4 are independently from each other selected from carbon or nitrogen atoms and form together with the carbon atoms they are attached to a
- 10 stable aromatic or heteroaromatic ring,
- G is monocyclic, bicyclic or tricyclic 4- to 15-membered saturated, or partially unsaturated heterocyclic ring containing in addition to the nitrogen atom of the lactam moiety 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said heterocyclic ring is unsubstituted or mono-, di-, tri- or four times
- 15 substituted independently of one another by oxo or by R5,
- R1, R2, R3, R4 and R5 are independent of one another identical or different and are
- a) hydrogen atom,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three
 - 20 times by R13,
 - c) halogen,
 - d) phenoxy-, wherein phenoxy is unsubstituted or substituted one to three times by R13,
 - e) -(C₁-C₃)-fluoroalkyl,
 - 25 f) -N(R10)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
 - g) -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,

- h) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- i) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- 5 j) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- k) $-O-CF_3$,
- 10 l) $-O-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- m) $-NO_2$,
- n) $-CN$,
- o) $-OH$,
- 15 p) $-C(O)-R_{10}$,
- q) $-C(O)-O-R_{11}$,
- r) $-C(O)-N(R_{11})-R_{12}$,
- s) $-N(R_{11})-R_{12}$,
- t) $-N(R_{10})-SO_2-R_{10}$,
- 20 v) $-S-R_{10}$,
- w) $-SO_n-R_{10}$, wherein n is 1 or 2,
- x) $-SO_2-N(R_{11})-R_{12}$ or
- y) at least one of R1, R2, R3 or R4 are absent in case one or more of J1, J2, J3 or J4 are nitrogen atom, or

25 R1 and R2, R2 and R3 or R3 and R4 form together with the atoms which they are attached to a 5- or 8- membered ring, containing up to 0, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said ring is unsubstituted or substituted one, two, three or four times by R14,

R10 is hydrogen atom, $-(C_1-C_3)$ -fluoroalkyl or $-(C_1-C_6)$ -alkyl,

30 R11 and R12 are independently of one another identical or different and are

a) hydrogen atom,

- b) $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- c) $-(C_6-C_{14})$ -aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 d) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13 or

R13 is halogen, $-NO_2$, $-CN$, $=O$, $-OH$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkoxy, $-CF_3$, phenyloxy-, $-C(O)-R_{10}$, $-C(O)-O-R_{17}$, $-C(O)-N(R_{17})-R_{18}$, $-N(R_{17})-R_{18}$, $-N(R_{10})-SO_2-R_{10}$, $-S-R_{10}$, $-SO_n-R_{10}$, wherein n is 1 or 2, $-SO_2-N(R_{17})-R_{18}$,

- 10 $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or a 3- to 7-membered
- 15 cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,


R14 is halogen, $-OH$, $=O$, $-CN$, $-CF_3$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_4)$ -alkoxy, $-NO_2$, $-C(O)-OH$, $-NH_2$, $-C(O)-O-(C_1-C_4)$ -alkyl, $-(C_1-C_8)$ -alkylsulfonyl,

20 $-C(O)-NH-(C_1-C_8)$ -alkyl, $-C(O)-N-[(C_1-C_8)\text{-alkyl}]_2$, $-C(O)-NH_2$, $-S-R_{10}$, $-N(R_{10})-C(O)-NH-(C_1-C_8)$ -alkyl, or $-N(R_{10})-C(O)-N-[(C_1-C_8)\text{-alkyl}]_2$,


R17 and R18 are independently of one another identical or different and are

- a) hydrogen atom,
- b) $-(C_1-C_6)$ -alkyl,
- 25 c) $-(C_6-C_{14})$ -aryl- or
- d) $-(C_4-C_{14})$ -heteroaryl,


said process comprises a reaction of a compound of formula II



wherein R1, R2, R3, R4, J1, J2, J3 and J4 are as defined in formula I and X is Cl, Br, I, triflate or nonaflate, with a compound of formula III



- 5 wherein ring G are as defined in formula I,
in the presence of a metal catalyst, a base, a ligand and an aprotic solvent to
give a compound of formula IV



- 10 and converting the compound of formula IV into a compound of formula I in the
presence of a reducing reagent and a second solvent and
optionally the compound of formula I is converted to its physiologically tolerated
salt.

- 15 2. The process according to claim 1, wherein a compound of formula I is prepared,
wherein palladium or copper are used as metal catalyst.
- 20 3. The process according to claims 1 or 2, wherein a compound of formula I is
prepared, wherein
J1, J2, J3 and J4 form together with the carbon atoms they are attached to a
ring selected from benzene, pyrazine, pyridazine, pyridine, pyrimidine, triazine
or tetrazine,

G is selected from azetidine, azepane, azocane, aza-bicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, azacyclooctanone, azacyclononanone, aza-tricyclo[4.3.1.1*3,8*]undecane, 4,4-dimethyl-3,5-dioxazatricyclo[5.2.1.0*2,6*]-decane, 3,5-dioxazatricyclo[5.2.1.0*2,6*]decane, 4,4-dimethyl-3,5-dioxazatricyclo[5.2.1.0*2,6*]decan-9-one, azocane-2-one, azonane, 1,4-diazepane, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, imidazoline, imidazolidine, isothiazolidine, isoxazolidine, ketopiperazine, morpholine, [1,4]oxazocane, [1,3]oxazocan-2-one, piperazine, piperidine, pyrazoline, pyrazolidine, 1,2-dihydro-pyridine, pyrrolidine, pyrrolidinone, 2,3-dihydro-1H-pyrrole, pyrroline, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydropyridine, thiadiazine, thiazolidine, thiazoline or thiomorpholine, wherein G is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by oxo or by R5,

R1, R2, R3, R4 and R5 are independent of one another identical or different and are

- a) hydrogen atom,
- b) F,
- c) Cl,
- d) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,
- e) -(C₁-C₃)-fluoroalkyl,
- f) phenyl, wherein phenyl is unsubstituted or substituted one to three times by R13,
- g) -(C₄-C₁₄)-heteroaryl, wherein heteroaryl is selected from acridinyl, azaindole (1H-pyrrolopyridinyl), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolynyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 3,3-dioxo[1,3,4]oxathiazinyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolynyl, imidazolyl, indanyl, 1H-indazolyl, indolinyl, indolizynyl, indolyl, 3H-

- indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, oxetanyl, oxocanyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyrazolo[3,4-b]pyridine, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranly, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydrofuranly, tetrahydropyranly, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranly, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,, and is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,
- h) $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13, or
- i) a 3- to 7-membered cyclic residue is selected from azepine, azetidine, aziridine, azirine, 1,4 diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine,

oxetan, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, and is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13,

j) -O-CF₃,

k) -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,

l) -N(R10)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13,

m) -CN,

n) -OH,

o) phenyloxy-, wherein phenyloxy is unsubstituted or substituted one to three times by R13,

p) -C(O)-O-R11,

q) -C(O)-N(R11)-R12,

r) -N(R11)-R12,

s) -N(R10)-SO₂-R10,

t) -S-R10,

v) -SO_n-R10, wherein n is 1 or 2,

w) -SO₂-N(R11)-R12,

x) -C(O)-R10 or

y) at least one of R1, R2, R3 or R4 are absent in case one or more of J1, J2, J3 or J4 are nitrogen atom,

R10 is hydrogen atom, -(C₁-C₃)-fluoroalkyl or -(C₁-C₆)-alkyl,

R11 and R12 are independently of one another identical or different and are

a) hydrogen atom,

- b) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 5 d) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13 or

R13 is F, Cl, -CN, =O, -OH, $-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkoxy, -CF₃, phenyloxy-, -C(O)-R10, -C(O)-O-R17, -C(O)-N(R17)-R18, -N(R17)-R18, 10 -N(R10)-SO₂-R10, -S-R10, -SO_n-R10, wherein n is 1 or 2, -SO₂-N(R17)-R18, phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, $-(C_3-C_6)$ -cycloalkyl, wherein said 15 cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or a 3- to 7-membered cyclic residue, which is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is F, Cl, -OH, =O, -CN, -CF₃, $-(C_1-C_8)$ -alkyl, $-(C_1-C_4)$ -alkoxy, -C(O)-OH, 20 -NH₂, -C(O)-O- $-(C_1-C_4)$ -alkyl, $-(C_1-C_8)$ -alkylsulfonyl, -C(O)-NH₂, -C(O)-NH- $-(C_1-C_8)$ -alkyl, -C(O)-N- $[(C_1-C_8)$ -alkyl]₂, -S-R10, -N(R10)-C(O)-NH- $-(C_1-C_8)$ -alkyl or -N(R10)-C(O)-N- $[(C_1-C_8)$ -alkyl]₂,


R17 and R18 are independently of one another identical or different and are

- a) hydrogen atom,
- 25 b) $-(C_1-C_4)$ -alkyl,
- c) phenyl or
- d) $-(C_4-C_{14})$ -heteroaryl, wherein heteroaryl is as defined above and


X is Cl, Br or I.

- 30 4. The process according to claim 1 wherein one of the following compounds of formula I is prepared:

- 2,3-Dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;
 7-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;
 6-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;
 7-Methoxy-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole;
 5 5-Methyl-2,3-dihydro-1*H*-benzo[d]pyrrolo[1,2-*a*]imidazole-6-carboxylic acid
 methyl ester;
 2-Methoxy-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine;
 2,6-Dimethyl-7,8-dihydro-6*H*-pyrrolo[2',1':2,3]imidazo[4,5-*b*]pyridine;



- 10 1,2,3,4-Tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine;
 3,9-Dimethyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*;3',2'-*d*]imidazole;
 7-Chloro-4,4-diphenyl-1,2,3,4-tetrahydro-benzo[4,5]imidazo[1,2-*a*]pyridine;
 Dimethyl-(*S*)-7,8,9,10-tetrahydro-6*H*-benzo[4,5]imidazo[1,2-*a*]azepin-6-yl-amine;
 3-Methyl-5,6,7,8,9,10-hexahydro-4,4*b*,11-triaza-cycloocta[*a*]indene;
 15 2-Methyl-6,7,8,9,10,11-hexahydro-5*H*-4,4*b*,12-triaza-cyclonona[*a*]indene;
 3-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*;3',2'-*d*]imidazole;



- 2-Methyl-8,8-diphenyl-6,7,8,9-tetrahydro-dipyrido[1,2-*a*:3',2'-*d*]imidazole;
 5,6,7,8,9,10-Hexahydro-1,4*b*,11-triaza-cyclooct[*a*]indene; or
 20 3-Methoxy-6,7,8,9,10,11-hexahydro-5*H*-4,4*b*,12-diaza-cyclonon[*a*]indene.

5. The process according to claims 1 or 2, wherein the palladium catalyst is selected from: Pd-alkanoates, Pd-alkanoate complexes, Pd-acetonates, Pd-halides, Pd-halide complexes and Pd-phosphine complexes.

- 25 6. The process according to claim 5, wherein the palladium catalyst is selected from: palladium (II) acetate, palladium (II) trifluoroacetate, tris(dibenzylideneacetone)dipalladium(0), tris(dibenzylideneacetone)dipalladium(0) chloroform

- adduct, palladium (II) chloride, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-palladium(II) chloride, acetato(2'-di-tert-butylphosphino-1,1'-biphenyl-2-yl)palladium(II), (1,2-Bis(diphenylphosphino)ethane)dichloropalladium(II), Bis[1,2-bis(diphenylphosphino)ethane]palladium (0), [(2S,3S)-
- 5 Bis(diphenylphosphino)-butane] [eta3-allyl]palladium(II) perchlorate, and 1,3-bis(2,4,6-trimethylphenyl)-imidazol-2-ylidene(1,4-naphthoquinone)palladium (0) dimer.
7. The process according to claims 1 or 2, wherein the copper catalyst is selected from: copper (I) halogen salts and copper oxides.
- 10 8. The process according to claim 7, wherein the copper catalyst is selected from: copper (I) chloride, copper (I) bromide, copper (I) iodide and copper (I) oxide.
- 15 9. The process according to claims 1 to 8, wherein the base is selected out of the group of carbonates, phosphates, fluorides, alkoxides and hydroxides with a suitable metal as counter ion.
10. The process according to claim 9, wherein the base is selected out of the group: 20 potassium carbonate, potassium phosphate and caesium carbonate.
11. The process according to claims 1, 2, 5, 6, 9 and 10, wherein the ligand is selected out of the group: (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene, 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene, (R)-(-)-1-[(S)-2-
- 25 (diphenylphosphino) ferrocenyl] ethyldicyclohexylphosphine, 1,2-Bis(diphenylphosphino)ethane, 1,3-Bis(diphenylphosphino)propane, (R)-(-)-1-[(S)-2-(Dicyclohexylphosphino)-ferrocenyl]ethyldi-tert-butylphosphine, (R)-(+)-1,1'-Bis(diphenylphosphino)-2,2'-bis(*N,N*-diisopropylamido)ferrocene, (S,S)-1-[1-(Di-tert-butylphosphino)ethyl]-2-(diphenylphosphino)ferrocene, (1*R*,2*R*)-(+)-
- 30 1,2-Diaminocyclohexane-*N,N'*-bis(2-diphenylphosphino-1-naphthoyl), (-)-1,2-Bis((2*S*,5*S*)-2,5-diisopropylphospholano)-benzene, Bis[(2-diphenylphosphino)phenyl]ether, (S)-(-)-2,2'-Bis(di-para-tolylphosphino)-1,1'-

binaphyl, 4,5-Bis(bis(3,5-bis(trifluoromethyl)phenyl)-phosphino)-9,9-dimethylxanthen, 2,2'-bis[(2',4',6'-triisopropyl)dicyclohexyl-phosphino]biphenyl, and 2,2'-bis(di-*tert*-butylphosphino)biphenyl, tri-*tert*-butylphosphine.

- 5 12. The process according to claims 1, 2, 7, 8, 9 and 10, wherein the ligand is selected out of the group: ethylenediamine, *N*-methylethylenediamine, *N,N'*-dimethyl-ethane-1,2-diamine, *N,N*-dimethyl-ethane-1,2-diamine *N*-buthylethylenediamine, *N,N*-dimethylethylenediamine, *N,N,N'*-trimethylthylenediamine, *N,N,N,N'*-tetramethylthylenediamine, *trans*-1,2-cyclohexanodiamine, *cis*-1,2-cyclohexanodiamine, *cis/trans*-1,2-cyclohexanodiamine, *N,N'*-dimethyl-1,2-cyclohexanodiamine, *N,N'*-diethyl-1,2-cyclohexanodiamine, *N,N'*-dipropyl-1,2-cyclohexanodiamine, 1,3-propylenediamine, 1,2-benzenediamine, phenanthridine, acridine, acridine orange, 9-aminoacridine, 9-hydroxy-4-methoxyacridine, proflavine, 4-(2-pyriylazo) resorcinol, 1,2-dihydro-1-(2-(2-pyridyl)-ethyl)-3,6-pyridazinedione, [1,10]phenanthroline, 5-nitro-[1,10]phenanthroline, bathophenanthroline, spiramycin, bicinehonic acid sodium salt (bca), 1-(4-pyridyl) pyridinium chloride, 2-pyridylacetic acid hydrochloride, 8-mercaptoquinoline hydrochloride, dimethylamino acetic acid, picolinic acid, 3-hydroxypicolinic acid, 3-hydroxy
 - 10
 - 15
 - 20
 - 25
 - 30
- picolinamide, glycol, pyridine, 2-aminopyridine, 2-hydroxypyridine, 3-cyanopyridine, 4-cyanopyridine, 2-ethylpyridine, 2-amino-6-methylpyridine, 2-(aminomethylpyridine), 2-(hydroximethylpyridine), 2-hydroxi-6-methylpyridine, 2-dimethylaminopyridine, 4-dymethylaminopyridine, 2-(2-hydroxiethyl)pyridine, 4-*tert*-butylpyridine, 3-acetoxypyridine, 2-phenylpyridine, 4-phenylpyridine, 4-benzoylpyridine, 2-(2-thienyl)pyridine, 2-benzylpyridine, 2-anilinopyridine, 3-pyridinepropanol, 1-(2-pyridyl) piperazine, di-2-pyridyl ketone, ethyl 2-pyridyl acetate, 2-(2-diethylaminoethyl)-pyridine, 4-(2-diethylaminoethyl)pyridine, 2,6-di-*tert*-butyl pyridine, (*S,S*)-2,6-bis(4-isopropyl-2-oxazolin-2-yl) pyridine, 2,3-pyridine dicarboxylic acid, 2,6-pyridine dicarboxylic acid, 3,5-pyridine dicarboxylic acid, 1,3-di(4-pyridyl)propane, 2,3-di-3-pyridyl-2,3-butanediol, 2,2'-bipyridine, 2,2-dipyridyl, 4,4'-dimethyl-2,2'-dipyridyl, 3-hydroxypyridine, 2-mercaptopyridine, 2-(2-methylaminoethyl) pyridine, 3-hydroxi picolinamine, 3-

hydroxypicolinic acid, 2,2':6',2''-terpyridine, 2-picoline, 6,6'-bi-2-picoline, 2,4-lutidine, 2,6-lutidine- α -2,3-diol, 2,6-lutidine 2,4,6-collidine, picolinamide, ethyl picolinate, ethyl isonicotinate, quinoline, 2-phenylquinoline, 8-hydroxyquinoline, 8-acetoxyquinoline, 2-methyl-8-nitroquinoline, 7,8-benzoquinoline, 2-quinolinol, 2-quinolinethiol, quinoline-4-carboxylic acid, 2-phenyl-4-quinoline carboxylic acid, 2,4-hydroxy quinoline monosodium salt, 8-ethoxyquinoline-5-sulfonic acid sodium salt, 8-hydroxy-5-nitroquinoline, 4-chloro-7-(trifluoromethyl) quinoline, 8-hydroxyquinoline-5-sulfonic acid monohydrate, 5-nitroquinaldic acid, isoquinoline, isoquinoline-3-carboxylic acid hydrate, 1,4,5-triazanaphtalene, quinaldine, 4-chloroquinaldine, nicotine, isonicotinamine, neocuproine, glycine, *N*-methylglycine, *N,N*-dimethylglycine, glycine hexyl ester, lysine, cystine, α -alanine, arginine, cysteine, β -alanine.

13. The process according to claims 1 to 12, wherein the aprotic solvent is selected out of the group: benzene, toluene, xylene, mesitylene, acetonitrile, tetrahydrofuran, dimethylformamide, *n*-methylpyrrolidinone, dimethylacetamide, dimethylsulfoxide, (2-methoxyethyl)ether and pyridine.

14. The process according to claims 1 to 13, wherein the reaction between the compound of formula II and formula III is carried out in the temperature range from 60 °C to 150 °C, preferably from 70 °C to 90 °C.

15. The process according to claims 1 to 14, wherein the second solvent is selected out of the group: methanol, ethanol, propanol, acetic acid, methylene chloride, dimethylformamide, tetrahydrofuran, pyridine, *p*-xylene, ethylacetate, benzene, toluene, xylene, mesitylene and acetonitrile.

16. The process according to claim 15, wherein the second solvent is selected out of the group: methanol, ethanol, acetic acid, methylene chloride, dimethylformamide, pyridine and *p*-xylene.

17. The process according to claims 1 to 16, wherein the reducing reagent is selected out of the group: $\text{H}_2/\text{Raney-Ni}$, $\text{H}_2/\text{Pd-C}$, H_2/PtO_2 , H_2/Ru , $\text{NaBH}_4/\text{NiCl}_2$, $\text{NaBH}_4/\text{FeCl}_2$, $\text{H}_3\text{PO}_2/\text{Pd-C}$, Sn/HCl , SnCl_2/HCl , Fe/HOAc , Fe/HCl , FeSO_4/HCl , Fe/FeSO_4 , Zn/HCl , Na_2S , and $\text{Na}_2\text{S}_2\text{O}_4$.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/004638

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D471/04 C07D471/14 C07D487/04 C07D491/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2006/058064 A (MERCK & CO.) 1 June 2006 (2006-06-01) page 27, line 10 - line 15; claim 1; example 1	1-17
Y	WEI DENG ET. AL.: "Amino acid mediated Goldberg reactions between amides and aryl iodides." TETRAHEDRON LETTERS, vol. 45, 2004, pages 2311-2315, XP002494869 cited in the application table 4	1-17
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 September 2008

Date of mailing of the international search report

23/09/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, Ian

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/004638

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	R. G. BROWNING ET. AL.: "Palladion catalyzed aryl-amidation. Synthesis of non-racemic N-aryl lactams" TETRAHEDRON, vol. 60, 2004, pages 359-365, XP002494870 cited in the application table 1 -----	1-17
Y	DATABASE WPI Week 199128 1991, Thomson Scientific, London, GB; AN 1991-205956 XP002494871 "Dihydro-pyrrolo benzimidazole sulphonamide production used as plant growth promoters and intermediates in production of pesticides and medicines." & SU 1 587 052 A (PLANTS CHEM PROTECT) 1988 abstract -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/004638

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006058064	A	01-06-2006	
		AU 2005309606 A1	01-06-2006
		CA 2587800 A1	01-06-2006
		CN 101065357 A	31-10-2007
		EP 1819674 A2	22-08-2007
		JP 2008521813 T	26-06-2008
<hr/>			
SU 1587052	A	23-08-1990	NONE
<hr/>			